|
|
Separation, determination of six impurities in methotrexate drug substance using ultra-performance liquid chromatography |
Cai-Sheng Wua, Cai-Hong Wanga, Jin-Lan Zhanga, Dong-Mei Wangb, Yuan-Feng Tongb, Song Wub, Hai-Wei Huangc, Bao-Ming Ningc |
a State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China;
b Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China;
c National Institutes for Food and Drug Control, Beijing 100050, China |
|
|
Abstract Methotrexate (MTX) is an antineoplastic therapeutic medicine as antimetabolite of folic acid. In this paper, a sensitive and rapid ultra-performance liquid chromatographic (UPLC) method was developed and validated for the separation and determination of impurities in MTX drug substances. The UPLC method was accomplished on an Agilent Zorbax Extend C-18 (50 mm×4.6 mm, 1.8 mm) with a gradient elution system composed of sodium dihydrogen phosphate in water (20 mmol/L, pH 3.0) and acetonitrile. The flow rate was 2.2 mL/min. The method was validated. The calibration curves displayed good linearity (r > 0.999) within the tested concentration ranges. The limit of detection (LOD) and limit of quantification (LOQ) of the six analytes were all less than 0.774 μg/mL and 1.03 mg/mL. The relative standard deviation (RSD) for intra-and inter-day precision of the six analytes was less than 9.8%, including at the LOQ. The average recovery ranged from 95.2% to 103% except at the LOQ, where recovery ranged from 82.7% to 117%. The validated method was successfully used to determine the relative abundance of six impurities in the MTX drug substances.
|
Received: 30 August 2013
Published: 02 December 2013
|
Fund: We thank the Ministry of Public Health of the People's Republic of China (No. 200802038) and the Ministry of Science and Technology of the People's Republic of China (No. 2011IM030200) for financial support of this work. |
Corresponding Authors:
Jin-Lan Zhang
E-mail: zhjl@imm.ac.cn
|
|
|
|
[9] |
D.A. El-Hady, N.A. El-Maali, R. Gotti, et al., Methotrexate determination in pharmaceuticals by enantioselective HPLC, J. Pharm. Biomed. Anal. 37 (2005) 919-925.
|
[4] |
S. Shen, T. O'Brien, L.M. Yap, H.M. Prince, C.J. McCormack, The use of methotrexate in dermatology: a review, Australas. J. Dermatol. 53 (2012) 1-18.
|
[1] |
European Pharmacopoeia, European Directorate for the Quality of Medicines & Health Care, 7th ed., European Pharmacopoeia, Strasbourg, 2010, pp. 2467-2469.
|
[3] |
Methotrexate, Wikipedia, http://en.wikipedia.org/wiki/Methotrexate.
|
[2] |
R. Gotti, D.A. El-Hady, V. Andrisano, et al., Determination of the chiral and achiral related substances of methotrexate by cyclodextrin-modified micellar electrokinetic chromatography, Electrophoresis 25 (2004) 2830-2837.
|
[5] |
The Stationery Office, The British Pharmacopoeia Commission British Pharmacopoeia, The Stationery Office, 2012, pp. 1427-1429.
|
[8] |
C.S. Wu, Y.F. Tong, P.Y. Wang, et al., Identification of impurities in methotrexate drug substances using high-performance liquid chromatography coupled with a photodiode array detector and Fourier transform ion cyclotron resonance mass spectrometry, Rapid Commun. Mass Spectrom. 27 (2013) 971-978.
|
[10] |
K. Michail, M.S. Moneeb, Determination of methotrexate and indomethacin in urine using SPE-LC-DAD after derivatization, J. Pharm. Biomed. Anal. 55 (2011) 317-324.
|
[11] |
M. Uchiyama, T. Matsumoto, T. Matsumoto, et al., Simple and sensitive HPLC method for the fluorometric determination of methotrexate and its major metabolites in human plasma by post-column photochemical reaction, Biomed. Chromatogr. 26 (2012) 76-80.
|
[12] |
S. Fang, C.P. Lollo, C. Derunes, M.J. LaBarre, Development and validation of a liquid chromatography method for simultaneous determination of three process-related impurities: yeastolates, triton X-100 and methotrexate, J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 879 (2012) 3612-3619.
|
[14] |
G. Chen, J.P. Fawcett, M. Mikov, et al., Simultaneous determination of methotrexate and its polyglutamate metabolites in Caco-2 cells by liquid chromatographyandem mass spectrometry, J. Pharm. Biomed. Anal. 50 (2009) 262-266.
|
[15] |
E. den Boer, S.G. Heil, B.D. van Zelst, et al., A U-HPLC-ESI-MS/MS-based stable isotope dilution method for the detection and quantitation of methotrexate in plasma, Ther. Drug Monit. 34 (2012) 432-439.
|
[7] |
The Pharmacopoeia Commission of PRC, The Pharmacopoeia of the People's Republic of China. Part Ⅱ, China Medical Science and Technology Press, Beijing, 2010p. 149.
|
[6] |
The United States Pharmacopeial Convention, The 35th revision of the United States Pharmacopeia (USP 35) and the 30th edition of the National Formulary (NF 30), Rockville, MD, 2011, pp. 3855-3857.
|
[13] |
H.L. Cheng, S.S. Chiou, Y.M. Liao, et al., Analysis of methotrexate and its eight metabolites in cerebrospinal fluid by solid-phase extraction and triple-stacking capillary electrophoresis, Anal. Bioanal. Chem. 398 (2010) 2183-2190.
|
[16] |
ICH Guidelines, Impurities in new drug substances Q3A(R2), October 2006.
|
|
|
|